AceLink Therapeutics, Inc

Website
39600 Eureka Dr Ste 151
Newark, CA 94560

AceLink Therapeutics, Inc. is a clinical-stage drug development company based in Newark, CA, specializing in groundbreaking therapies for diseases related to glycolipid metabolism. The company boasts a seasoned team of professionals with extensive knowledge in glycolipid biology, rare genetic diseases, and drug development, collaborating with a broad network of research organizations and academic leaders.

Among its lead programs, AL1211 is a non-brain penetrant glucosylceramide synthase (GCS) inhibitor currently undergoing Phase 2 trials for Fabry disease and type I Gaucher disease. Additionally, AL0804, a highly brain-penetrant GCS inhibitor, targets neuronopathic glycolipid storage diseases, while AL1311 is a potent NRF2 activator being developed for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Generated from the website

Own this business?
See a problem?

You might also like

United StatesCaliforniaNewarkAceLink Therapeutics, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.